Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765578 · ClinicalTrials.gov registry record
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 1,713
- Enrollment target
NCT05765578: Completed study, sponsored by ModernaTX.
NCT05765578 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 1,713 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05765578 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 1,713 participants
- Enrollment target
Study Summary
The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5).
Interventions
- BIOLOGICAL Moderna COVID-19 Vaccine
- BIOLOGICAL Moderna mRNA1273.222 Booster
- BIOLOGICAL Pfizer COVID-19 Vaccine
- BIOLOGICAL Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)
- BIOLOGICAL Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,713 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2024-06-17 |
What the finished NCT05765578 record still lists
NCT05765578 is an observational study that tracks outcomes without assigning an intervention. Its 1,713 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which Moderna COVID-19 Vaccine is the first listed.
NCT05765578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05765578 about?
NCT05765578 is a clinical study titled "An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)". The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5).
What is the current status of trial NCT05765578?
This trial is currently completed. The enrollment target is 1,713 participants. The study started on 2023-03-08. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT05765578?
The interventions under investigation include: Moderna COVID-19 Vaccine (BIOLOGICAL), Moderna mRNA1273.222 Booster (BIOLOGICAL), Pfizer COVID-19 Vaccine (BIOLOGICAL), Moderna 2023 Updated COVID-19 vaccine (XBB.1.5) (BIOLOGICAL), Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05765578?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI